Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579888 · ClinicalTrials.gov registry record · Phase 1
CD19-Specific T Cells Post AlloSCT
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03579888: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03579888 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03579888, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small lymphocytic lymphoma, or chronic lymphocytic lymphoma. Sometimes researchers change the genetic material in the cells of a patient's T cells using a process called gene transfer. Researchers then inject the changed T-cells into the patient's body. Receiving the T-cell infusion may help to control the disease.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-06-26 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579888
The ClinicalTrials.gov registry entry for NCT03579888 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03579888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579888 about?
NCT03579888 is a clinical study titled "CD19-Specific T Cells Post AlloSCT". This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small lymphocytic lymphoma, or chronic lymphocytic lymphoma. Sometimes researche...
What is the current status of trial NCT03579888?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-06-26. Estimated completion is 2021-05-27.
What interventions are being tested in trial NCT03579888?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03579888?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.